FAM115C Inhibitors
FAM115C inhibitors represent a specialized category of chemical compounds that indirectly attenuate the activity of FAM115C by intervening in distinct signaling pathways and cellular processes to which FAM115C is intrinsically connected. One of the prominent inhibitors, Rapamycin, binds to FKBP12, and the resulting complex staunchly inhibits the mTOR pathway, a critical regulator of autophagy, a process that FAM115C is suggested to modulate. The inhibition of mTOR by Rapamycin, therefore, could lead to an enhancement of autophagic activity, which is inversely related to the functional activity of FAM115C. On a similar note, LY294002 and Wortmannin are inhibitors of PI3K, which is upstream of AKT signaling. The inhibition of PI3K and consequent reduction in AKT phosphorylation might impede the activation of FAM115C, presuming that FAM115C is associated with the PI3K/AKT pathway. Thus, the blockade of this pathway by these inhibitors would result in the indirect suppression of FAM115C activity.
In addition to these, other inhibitors like Staurosporine and U0126 target protein kinases and the MEK/ERK pathway respectively, pathways that could phosphorylate FAM115C or are necessary for its activation. Staurosporine's broad-spectrum kinase inhibition could preclude phosphorylation events critical for FAM115C's functionality, while U0126's specific inhibition of MEK, thereby thwarting ERK activation, could similarly result in the downregulation of FAM115C activity. Bortezomib, an inhibitor of proteasomal degradation, could indirectly influence FAM115C by stabilizing regulatory proteins that are ubiquitinated for degradation, potentially leading to a buildup of non-functional FAM115C. Additionally, 17-AAG, through its inhibition of Hsp90, could destabilize FAM115C if its proper folding or function is contingent upon Hsp90 association. Each inhibitor operates through a distinct mechanism yet converges on the common outcome of diminishing FAM115C's action within the cell, providing a multi-angled approach to the indirect suppression of this protein's activity.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin binds to FKBP12 and the complex inhibits mTOR (mammalian target of rapamycin). Since mTOR is a key regulator of autophagy, and FAM115C is suggested to be involved in the regulation of autophagic processes, rapamycin can indirectly inhibit the functional activity of FAM115C by promoting autophagy. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a potent inhibitor of protein kinases. It can inhibit various kinases that might phosphorylate FAM115C, thereby potentially reducing FAM115C's activity by preventing its post-translational modification which is essential for its function. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A PI3K inhibitor that prevents the phosphorylation and activation of AKT. As FAM115C might interact with the PI3K/AKT pathway, inhibition of PI3K could lead to decreased activity of FAM115C by preventing necessary signaling events for its activation. | ||||||
Wiskostatin | 253449-04-6 | sc-204399 sc-204399A sc-204399B sc-204399C | 1 mg 5 mg 25 mg 50 mg | $49.00 $124.00 $441.00 $828.00 | 4 | |
WZB117 inhibits GLUT1, leading to a reduction in glucose uptake. If FAM115C is dependent on glycolytic metabolism for its activity, reducing glucose uptake could indirectly inhibit the functional activity of FAM115C. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
A proteasome inhibitor that can prevent the degradation of ubiquitinated proteins. If FAM115C is regulated by proteasomal degradation, bortezomib could lead to an accumulation of non-functional FAM115C or its regulators, indirectly inhibiting its activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
An inhibitor of MEK, which in turn prevents the activation of ERK. If FAM115C is acting downstream of the ERK pathway, inhibiting MEK may result in reduced functional activity of FAM115C by blocking necessary phosphorylation events. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
Another MEK inhibitor that can similarly inhibit ERK activation. Similar to PD98059, if FAM115C functions downstream of the ERK pathway, its activity could be indirectly inhibited through U0126-mediated blockade of ERK pathway signaling. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of JNK (c-Jun N-terminal kinases), which are a part of the MAPK family. If FAM115C is regulated by JNK signaling, inhibition of JNK could indirectly decrease the functional activity of FAM115C. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
This compound inhibits p38 MAP kinase, which is involved in stress responses. Inhibition of p38 could indirectly affect FAM115C if FAM115C is modulated as part of cellular stress responses. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
A potent inhibitor of PI3K like LY294002. It could lead to a decrease in FAM115C activity by a similar mechanism, preventing activation of downstream targets in the PI3K pathway that may be necessary for FAM115C activity. | ||||||